Related references
Note: Only part of the references are listed.The do's and don'ts of p53 isoforms
Reiner U. Jaenicke et al.
BIOLOGICAL CHEMISTRY (2009)
Functional characterization of p53β and p53γ, two isoforms of the tumor suppressor p53
Vilma Graupner et al.
CELL CYCLE (2009)
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin
Kelly A. Avery-Kiejda et al.
CLINICAL CANCER RESEARCH (2008)
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer
Mirko Marabese et al.
EUROPEAN JOURNAL OF CANCER (2008)
Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?
Olga Anczukow et al.
HUMAN MUTATION (2008)
Expression of novel p53 isoforms in oral lichen planus
Majid Ebrahimi et al.
ORAL ONCOLOGY (2008)
The diploid genome sequence of an individual human
Samuel Levy et al.
PLOS BIOLOGY (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells
J. Yu et al.
CELL DEATH AND DIFFERENTIATION (2007)
Expression of p53 isoforms in squamous cell carcinoma of the head and neck
Linda Boldrup et al.
EUROPEAN JOURNAL OF CANCER (2007)
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer:: Evidence for a crucial p53-p73 cross-talk in vivo
N Concin et al.
CLINICAL CANCER RESEARCH (2005)
Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate:: correlation with Gleason score
M Guan et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients
T Shiraiwa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
p53 isoforms can regulate p53 transcriptional activity
JC Bourdon et al.
GENES & DEVELOPMENT (2005)
Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer.: Evidence for their role as epigenetic p53 inhibitors in vivo
N Concin et al.
CANCER RESEARCH (2004)
How many mutant p53 molecules are needed to inactivate a tetramer?
WM Chan et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
ΔNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation
N Slade et al.
CELL DEATH AND DIFFERENTIATION (2004)
Quantitative TP73 transcript analysis in hepatocellular carcinomas
T Stiewe et al.
CLINICAL CANCER RESEARCH (2004)
Role of methylation in the control of Delta Np73 expression in neuroblastoma
I Casciano et al.
CELL DEATH AND DIFFERENTIATION (2002)
The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation
G Fontemaggi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay
PM Duddy et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2000)
p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts
KP Magnusson et al.
GENE (2000)
Share Paper
